Resona Asset Management Co. Ltd. Boosts Stock Position in Amgen Inc. $AMGN

Resona Asset Management Co. Ltd. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.1% in the first quarter, Holdings Channel reports. The institutional investor owned 176,626 shares of the medical research company’s stock after purchasing an additional 3,704 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Amgen were worth $62,052,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. WPG Advisers LLC boosted its holdings in Amgen by 16.9% in the first quarter. WPG Advisers LLC now owns 221 shares of the medical research company’s stock worth $78,000 after acquiring an additional 32 shares in the last quarter. Austin Asset Management Co Inc bought a new position in shares of Amgen during the first quarter valued at $221,000. CFS Investment Advisory Services LLC raised its position in shares of Amgen by 1.5% in the 1st quarter. CFS Investment Advisory Services LLC now owns 9,373 shares of the medical research company’s stock worth $3,330,000 after purchasing an additional 138 shares during the last quarter. W Advisors LLC purchased a new position in shares of Amgen in the 1st quarter worth about $210,000. Finally, Greenwood Capital Associates LLC boosted its stake in Amgen by 115.5% in the 1st quarter. Greenwood Capital Associates LLC now owns 30,444 shares of the medical research company’s stock worth $10,712,000 after purchasing an additional 16,318 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AMGN. Mizuho increased their price objective on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Canaccord Genuity Group initiated coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target on the stock. UBS Group raised their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Erste Group Bank restated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $355.73.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $367.99 on Thursday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The business has a 50-day simple moving average of $343.82 and a two-hundred day simple moving average of $348.97. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market cap of $198.61 billion, a price-to-earnings ratio of 25.61, a price-to-earnings-growth ratio of 3.63 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts expect that Amgen Inc. will post 22.35 earnings per share for the current year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Truist raised its price target on Amgen to $340 while keeping a hold rating, and Cantor Fitzgerald reaffirmed a neutral view, signaling that analysts still see value in the name even after the recent run-up. Benzinga analyst update
• Positive Sentiment: Biotech sentiment got a lift after Jim Cramer called the group “the hottest in the market,” citing a potentially stronger M&A environment that could benefit large-cap players like Amgen. Cramer biotech commentary
• Neutral Sentiment: Amgen’s dividend drew fresh attention, with an article arguing the payout still appears supported, but near-term headwinds could limit upside until operational concerns fade. Dividend safety article
• Negative Sentiment: Amgen initiated voluntary nationwide recalls of certain Corlanor and Sensipar lots due to foreign substances and CGMP deviations, raising quality-control and compliance concerns for investors. Recall coverage
• Negative Sentiment: Repeated recall headlines are putting Amgen’s manufacturing standards and risk profile back in focus, which could pressure the stock despite earlier momentum. Valuation and recall story
• Negative Sentiment: While Amgen won a preliminary injunction blocking Colorado’s proposed 70% price cap on Enbrel, that legal fight underscores ongoing pricing risk for one of its key drugs. Enbrel pricing article

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.